Table 2.
Baseline characteristics of the subjects.
| Variable | Control (n = 16) | Postinfarction HF (n = 32) |
|---|---|---|
| Age (years)Ɨ | 61.1 (12.4) | 62.4 (10.2) |
| Female¶ | 9 (56.3) | 17 (53.1) |
| Diabetes¶ | 4 (25.0) | 10 (31.3) |
| Hypertension¶ | 8 (50.0) | 15 (46.9) |
| Current smoker¶ | 3 (18.8) | 5 (15.6) |
| Triglycerides (mmol/l)Ɨ | 1.92 (1.62) | 1.58 (1.02) |
| Total cholesterol (mmol/l)Ɨ | 4.47 (1.81) | 4.00 (1.00) |
| LDL (mmol/l)Ɨ | 2.65 (1.13) | 2.54 (0.89) |
| HDL (mmol/l)Ɨ | 1.20 (0.26) | 1.05 (0.21) |
| Creatinine (μmol/l)Ɨ | 73.47 (11.20) | 84.47 (14.82) |
| β-Receptor blockers¶ | 4 (25.0) | 18 (56.3)∗ |
| ACE inhibitors or AR blockers¶ | 5 (31.3) | 20 (62.5)∗ |
| NT-proBNP (pg/ml)§ | 99.1 (71.5, 132.8) | 831.0 (152.5, 1605.0)∗ |
| Echocardiography | ||
| LVIDd (mm)Ɨ | 42.6 (2.3) | 54.1 (7.7)∗ |
| LVEDV (ml)Ɨ | 105.4 (34.6) | 159.9 (65.4)∗ |
| Ejection fraction (%)Ɨ | 73.2 (3.7) | 44.5 (9.4)∗ |
| Fractional shortening (%)Ɨ | 42.0 (2.8) | 21.3 (5.6)∗ |
| IVS (mm)Ɨ | 9.5 (1.9) | 10.3 (1.6) |
| LVPW (mm)Ɨ | 9.5 (1.8) | 9.8 (1.2) |
ƗMean (SEM), no. (%), and §median (25% percentile, 75% percentile) of nonnormally distributed variables. HF: heart failure; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; ACE: angiotensin-converting enzyme; AR: angiotensin receptor; NT-proBNP: N-terminal pro-B type natriuretic peptide; LVIDd: left ventricular internal end diastolic dimension; LVEDV: left ventricular end diastolic volume; IVS: interventricular septum; LVPW: left ventricular posterior wall. ∗P < 0.05 versus controls.